Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x
Impact News +++ Progressive Reports June 2025 Results (GlobeNewswire EN) +++ PROGRESSIVE CORP Aktie +3,43%

CYTOSORBENTS Aktie

 >CYTOSORBENTS Aktienkurs 
0.907 EUR    (Tradegate)
Ask: 0.951 EUR / 2630 Stück
Bid: 0.863 EUR / 2900 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 8 bis 22 Uhr!
CYTOSORBENTS Aktie über LYNX handeln
>CYTOSORBENTS Performance
1 Woche: +0,5%
1 Monat: -5,1%
3 Monate: -0,9%
6 Monate: -13,4%
1 Jahr: -9,2%
laufendes Jahr: +3,2%
>CYTOSORBENTS Aktie
Name:  CYTOSORBENTS CORP. DL-,01
Land:  USA
Sektor:  Gesundheit
ISIN/ Wkn:  US23283X2062 / A12GDU
Symbol/ Ticker:  HQE1 (Frankfurt) / CTSO (NASDAQ)
Kürzel:  FRA:HQE1, ETR:HQE1, HQE1:GR, NASDAQ:CTSO
Index:  -
Webseite:  http://www.cytosorbents.c..
Marktkapitalisierung:  -
Umsatz:  30.64 Mio. EUR
EBITDA:  -12.56 Mio. EUR
Gewinn je Aktie:  -0.56 EUR
Schulden:  23.4 Mio. EUR
Liquide Mittel:  10.05 Mio. EUR
Umsatz-/ Gewinnwachstum:  -2.9% / -
KGV/ KGV lG:  - / -
KUV/ KBV/ PEG:  - / 4.56 / -
Gewinnm./ Eigenkapitalr.:  -45.59% / -96.25%
Dividende je Aktie:  -
Dividendenrendite/ -schätzung:  - / -
Insiderhandel:  -
Suchwörter:  CYTOSORBENTS
Letzte Datenerhebung:  16.07.25
>CYTOSORBENTS Eigentümer
Aktien: 31.65 Mio. St.
f.h. Aktien: 54.32 Mio. St.
Insider Eigner: 15.29%
Instit. Eigner: 27.77%
>CYTOSORBENTS Peer Group

 
02.07.25 - 13:03
 CytoSorbents Provides U.S. FDA and Health Canada Regulatory Update for DrugSorb-ATR (PR Newswire)
 
PRINCETON, N.J., July 2, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update on its marketing applications for......
24.06.25 - 13:03
 CytoSorbents Files Appeal with U.S. FDA for Supervisory Review of its De Novo Request for DrugSorb™-ATR (PR Newswire)
 
PRINCETON, N.J., June 24, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that on June 18, 2025, it filed a request for......
29.05.25 - 13:01
 CytoSorbents to Participate at the Jefferies Global Healthcare Conference (PR Newswire)
 
PRINCETON, N.J., May 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that management will present and participate in......
22.05.25 - 15:30
 CytoSorbents Therapy Significantly Reduces Bleeding in Urgent CABG Patients on Ticagrelor in New Data Presented at EuroPCR 2025 (PR Newswire)
 
Real-World Analysis Shows Statistically Significant Reduction in Severe Bleeding and Transfusion Needs in CABG Patients on the Blood Thinner, Ticagrelor, with CytoSorbents Therapy PRINCETON, N.J., May 22, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the......
15.05.25 - 03:42
 Cytosorbents outlines plans for DrugSorb-ATR appeal and targets breakeven core business by second half 2025 (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
14.05.25 - 22:03
 CytoSorbents Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
 
PRINCETON, N.J., May 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today reported financial results for the first quarter ended March 31,......
01.05.25 - 22:21
 CytoSorbents Provides Regulatory Update for DrugSorb-ATR (PR Newswire)
 
PRINCETON, N.J., May 1, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in blood purification therapies for life-threatening conditions in the intensive care unit and cardiac surgery, today provided a regulatory update for DrugSorb™-ATR, its FDA-designated......
29.04.25 - 13:03
 CytoSorbents to Report First Quarter 2025 Financial Results and Recent Business Highlights (PR Newswire)
 
PRINCETON, N.J., April 29, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, will report first quarter 2025 financial results and recent business......
21.04.25 - 14:12
 CytoSorbents gets $1.7M from New Jersey business tax certificate transfer program (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.04.25 - 13:00
 CytoSorbents Receives Approximately $1.7 Million from the New Jersey Business Tax Certificate Transfer Program (PR Newswire)
 
PRINCETON, N.J., April 21, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced that it has received $1.7 million in cash proceeds......
17.04.25 - 13:06
 CytoSorbents Appoints Melanie Grossman, CPA as Vice President and Corporate Controller (PR Newswire)
 
Ms. Grossman brings 25 years of accomplished finance and accounting experience in global, publicly-traded companies Company announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) PRINCETON, N.J., April 17, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in......
14.04.25 - 13:03
 CytoSorbents Appoints Thomas Shannon as Vice President of Marketing for North America (PR Newswire)
 
PRINCETON, N.J., April 14, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, today announced the appointment of Thomas Shannon as Vice President of......
04.04.25 - 13:01
 CytoSorbents Extends Expiration Date of Outstanding Series B Right Warrants (PR Newswire)
 
PRINCETON, N.J., April 4, 2025 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, announced the extension of the expiration date of the Series B Right......
01.04.25 - 01:57
 Cytosorbents outlines 2025 growth strategy with $1B market potential for DrugSorb-ATR (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.03.25 - 22:27
 Cytosorbents Non-GAAP EPS of -$0.03, revenue of $9.15M (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
31.03.25 - 22:18
 CytoSorbents Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (PR Newswire)
 
2024 marked by strong commercial execution and improved operating leverage Company continues to expect DrugSorb-ATR regulatory decisions from Health Canada and US FDA in 2025 Successful Rights Offering and exercise of Series A Right Warrants strengthens balance sheet Strengthening of......
28.03.25 - 23:39
 Cytosorbents FY Earnings Preview (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
21.03.25 - 12:03
 CytoSorbents Reschedules Earnings Release to March 31, 2025 to Allow Additional Time to Complete Annual Audit (PR Newswire)
 
The Company reaffirms previously provided preliminary financial results for the quarter and full year ended December 31, 2024, and continues to expect regulatory decisions on DrugSorb™-ATR marketing applications in 2025 PRINCETON, N.J., March 21, 2025 /PRNewswire/ -- CytoSorbents......
04.03.25 - 13:03
 CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller (GlobeNewswire EN)
 
CytoSorbents Postpones Earnings Release to Allow More Time to Complete Annual Audit Following the Passing of Corporate Controller...
03.01.25 - 13:33
 CytoSorbents sees Q4 product revenue growth of 22%-25% Y/Y (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Vollkommene Politik besteht darin, niemals das letzte Motiv zu enthüllen. - Benjamin Disraeli
Partner:    >Tradegate Börse | >Dukascopy | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!